Area professor to join global cancer task force
Alderson Broaddus University is pleased to announce that Dr. Yi Charlie Chen, professor of biology, has been selected to join more than 350 cancer researchers from prominent research institutions in 31 countries in a project that hopes to tackle cancer’s complexity.
The initiative is called the Halifax Project and involves two separate task forces.
One task force will take what has been learned about cancer’s complexity to design an entirely new approach to therapy, while the other will assess whether or not everyday exposures to mixtures of commonly encountered chemicals have a role to play in cancer causation.
This collaborative international initiative is being led by a nongovernmental organization called Getting to Know Cancer. Within the project, Dr. Yi Charlie Chen will be working on one of 12 cross-functional teams of scientists that will each be focused on a different aspect of cancer biology.
“Dr. Chen is an exemplary faculty member on the Alderson Broaddus University campus,” said Joan Propst, provost and executive vice president for academic affairs at Alderson Broaddus University. “He is an exceptional teacher and researcher. It would be my hope that Dr. Chen’s involvement in this work would help in the ongoing study of cancer and in the quest for a cure. He is well-prepared for this work and will make significant contributions to the body of knowledge surrounding cancer.”
The teams will spend the next year reviewing what we now know about cancer’s complexity to design a groundbreaking broad-spectrum therapeutic approach that will be aimed at many prioritized targets simultaneously.
“For far too long, our mainstream model for treating cancer has been erroneously focused on mostly single intervention strategies,” said Keith I. Block, M.D., the medical and scientific director of the Block Center for Integrative Cancer Treatment in Skokie, Ill. “Because ag and driving malignant disease. However, we have since learned that cancer is a far more complex disorder with not one, but multiple defects. To overcome these defects – and be genuinely successful – an innovative, multi-pronged and multi-targeted approach to treatment is essential.”
“While we have worked quietly over many years on growing this multi-dimensional treatment model, the ‘Halifax Project’ represents the first global initiative that involves the collaboration of a large number of the very best cancer scientists and researchers from around the world,” Block continued. “Our team’s objective is to further evolve a comprehensive treatment model with less toxic and more innovative therapies, with the ultimate goal of eradicating cancer.”